By providing clearer nutrition information, the FDA hopes to empower consumers to make more informed food choices and contribute to long-term healthier eating patterns across the US.
'Mad Money' host Jim Cramer weighs in on stock including: Anavex Life Sciences, Sarepta Therapeutics, Viking Therapeutics, ...
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.
As the year gets underway, analysts and biotech executives highlight cell therapy’s pivot from oncology to autoimmune ...
OIG Recommends Changes in FDA Accelerated Approval After Flagging Concerns With Aduhelm, Other Drugs
The OIG recommended that the FDA define factors that would trigger an application's review by an agency council, which the agency disagreed with.
The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...
Currently, the DMD treatment landscape includes Sarepta’s Elevidys (delandistrogene moxeparvovec), the first FDA-approved ...
A trial team led by Latham’s Mike Morin and David Frazier and Finnegan’s William (Bill) Raich helped Sarepta Therapeutics ...
The review, which was spurred by controversy over the FDA's Aduhelm approval, recommends two main changes in agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback